|Chemical Name||enfortumab vedotin-ejfv|
|Dosage Form||Injectable (intravenous; 20 mg/vial, 30 mg/vial)|
|Drug Class||Monoclonal antibodies|
|Company||Astellas Pharma Inc.|
- Padcev is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.